Kwality Pharmaceuticals Ltd

Kwality Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Kwality Pharmaceuticals Ltd

₹ 885 -1.19%
08 Dec 11:12 a.m.
kwalitypharma.com BSE: 539997
About

Incorporated in 1983, Kwality Pharma is in the business of manufacturing & trading in Pharmaceuticals & allied products[1]

Key Points

Business Overview:[1][2]
KPL is in an ANVISA and EU GMP certified manufacturer of all pharma products including complex molecules across all dosage forms including niche Biologics. It has a portfolio of 3000+ formulations across 25+ therapeutic areas with categories including generics, cephalosporin, beta-lactam, oncology & biologics. It manufactures and deals in drugs intermediates, chemicals, extracts, alkaloids and other pharmaceutical goods, toilet requisites, medicines, beverages and other medical preparations

Website BSE
  • Market Cap ₹ 918 Cr.
  • Current Price ₹ 885
  • High / Low ₹ 1,235 / 596
  • Stock P/E 18.7
  • Book Value ₹ 281
  • Dividend Yield 0.00 %
  • ROCE 18.2 %
  • ROE 16.2 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has a good return on equity (ROE) track record: 3 Years ROE 15.5%
  • Company's median sales growth is 22.4% of last 10 years

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has high debtors of 154 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE SmallCap BSE Allcap

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025
56 56 69 67 70 78 92 80 90 84 116 111 111
40 41 57 54 54 61 71 63 70 67 90 87 86
Operating Profit 16 15 12 14 15 17 21 17 20 18 26 24 25
OPM % 28% 27% 17% 20% 22% 21% 23% 22% 22% 21% 22% 22% 23%
1 0 -15 0 0 1 -7 0 0 1 1 0 1
Interest 1 2 2 2 2 3 3 2 3 2 2 3 3
Depreciation 4 4 4 5 5 5 5 4 5 5 5 5 5
Profit before tax 11 10 -10 7 8 10 6 11 13 11 19 17 18
Tax % 20% 28% -24% 25% 24% 21% 28% 25% 33% 25% 24% 30% 23%
9 7 -7 5 6 8 4 8 8 9 14 12 14
EPS in Rs 8.72 6.97 -7.09 5.25 6.03 7.42 4.34 8.07 8.18 8.23 13.97 11.50 13.61
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
60 52 76 95 137 165 138 261 456 251 307 370 423
56 49 70 86 125 149 124 231 284 190 241 290 330
Operating Profit 4 4 6 9 12 15 14 29 172 61 67 80 93
OPM % 6% 7% 8% 9% 8% 9% 10% 11% 38% 24% 22% 22% 22%
0 1 0 2 1 1 4 2 4 -14 -5 2 3
Interest 1 1 1 2 2 2 3 3 3 7 10 10 10
Depreciation 1 1 2 2 3 3 4 6 11 15 20 18 19
Profit before tax 2 2 3 6 8 11 11 22 162 26 31 54 66
Tax % 47% 29% 39% 41% 38% 31% 24% 29% 26% 24% 24% 26%
1 1 2 3 5 8 8 15 120 19 24 40 49
EPS in Rs 0.95 1.32 1.89 3.31 4.51 7.28 8.12 14.86 115.70 18.76 23.11 38.44 47.31
Dividend Payout % 0% 0% 0% 9% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 22%
5 Years: 22%
3 Years: -7%
TTM: 24%
Compounded Profit Growth
10 Years: 41%
5 Years: 37%
3 Years: -31%
TTM: 43%
Stock Price CAGR
10 Years: %
5 Years: 72%
3 Years: 39%
1 Year: 0%
Return on Equity
10 Years: 27%
5 Years: 28%
3 Years: 15%
Last Year: 16%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Sep 2025
Equity Capital 4 4 5 5 10 10 10 10 10 10 10 10 10
Reserves 13 15 18 21 21 28 37 52 172 192 216 255 282
6 8 13 19 26 28 35 41 54 90 98 112 110
12 10 17 27 41 40 53 65 106 71 74 72 79
Total Liabilities 35 38 52 72 98 107 135 169 343 364 398 451 481
11 11 11 16 19 28 42 56 91 120 138 144 143
CWIP 0 0 0 0 0 0 0 3 12 14 0 0 0
Investments 3 4 5 7 9 8 8 9 4 4 4 4 4
21 23 36 50 70 71 86 102 236 226 256 303 335
Total Assets 35 38 52 72 98 107 135 169 343 364 398 451 481

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
-0 1 -3 4 -0 12 6 26 59 42 43 53
-4 -1 -2 -7 -6 -11 -17 -23 -63 -48 -26 -28
3 1 5 5 5 -2 12 1 6 1 -17 -14
Net Cash Flow -2 0 0 1 -1 -1 1 4 2 -5 -0 10

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 41 63 95 87 99 86 80 53 57 107 138 154
Inventory Days 58 61 54 72 54 34 94 38 97 310 187 167
Days Payable 58 40 61 67 79 52 96 58 63 117 106 112
Cash Conversion Cycle 41 85 89 92 74 68 78 33 91 300 219 209
Working Capital Days 60 35 41 21 19 21 43 25 62 120 103 100
ROCE % 12% 11% 15% 19% 19% 21% 18% 26% 97% 18% 16% 18%

Shareholding Pattern

Numbers in percentages

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
54.44% 54.73% 54.73% 54.76% 54.76% 54.82% 54.82% 54.82% 54.82% 54.82% 54.82% 54.82%
0.01% 0.01% 0.01% 0.01% 0.01% 0.00% 0.00% 0.02% 0.03% 0.32% 0.33% 0.33%
45.54% 45.25% 45.25% 45.22% 45.22% 45.17% 45.18% 45.15% 45.14% 44.86% 44.86% 44.83%
No. of Shareholders 5,3766,2116,9436,2915,7865,6955,2737,4878,9479,42010,11511,595

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls

  • Jun 2025
    Transcript
    AI Summary
    PPT
  • May 2024
    Transcript
    AI Summary
    PPT
  • May 2024
    Transcript
    AI Summary
    PPT
  • Aug 2023
    Transcript
    AI Summary
    PPT
  • May 2022
    Transcript
    AI Summary
    PPT